under the “other non-Enterobacterales” category, but most of the previous studies used various antimicrobial susceptibility testing methods and 2023 Breakpoint Implementation Toolkit (2023 BIT) Effective January 2024, clinical laboratories performing antimicrobial susceptibility testing (AST) will be required to use breakpoints currently recognized by Clinical and Laboratory Standards Institute (CLSI) or US Food and Drug Administration ( FDA )
W
If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1
This study was planned to ascertain the agreement in antimicrobial susceptibility using the Clinical and Laboratory Standards Institute (CLSI) and EUCAST breakpoints during the Kirby-Bauer
4 The Clinical and Laboratory Standards Institute (CLSI) is pleased to announce the recipients of its 2024 Excellence Awards
aeruginosa Ciprofloxacin ≤ 1 Levofloxacin ≤ 2 Organism Antimicrobial “S” MIC Enterobacterales Ciprofloxacin ≤ 0
cereus isolates from blood cultures showed MIC90 of levofloxacin as 4 (CLSI’s breakpoint of levofloxacin was ≤2 as sensitive)
Susceptibilities were assessed based upon historic CLSI breakpoints in 2010 as well as the current CLSI breakpoints from the most recent CLSI MIC breakpoints, the 29th edition of document M100, published in 2019
As antimicrobial susceptibility testing (AST) results for both levofloxacin and The 2019 CLSI revised the FQ susceptibility breakpoints for Enterobacterales to MICs of ≤0
Susceptible breakpoints were based mainly on blood levels related to toxicity, whereas resistant breakpoints were based on maximum blood levels achieved by these compounds
, and
maltophilia, the CLSI subcommittee ad-hoc working group (AHWG) evaluated multiple studies which used in vivo PK/PD models to evaluate levofloxacin efficacy against S